AstraZeneca’s (AZN) Hold Rating Reiterated at Deutsche Bank Aktiengesellschaft

by · The Markets Daily

Deutsche Bank Aktiengesellschaft reissued their hold rating on shares of AstraZeneca (LON:AZN – Free Report) in a research note released on Tuesday morning,Digital Look reports. The firm currently has a £117 target price on the biopharmaceutical company’s stock.

Several other analysts have also recently issued reports on the stock. Berenberg Bank lowered their target price on shares of AstraZeneca from £160 to £150 and set a “buy” rating on the stock in a research note on Tuesday, September 15th. Royal Bank Of Canada reissued an “outperform” rating and issued a £145 price target on shares of AstraZeneca in a research note on Tuesday, September 8th. Citigroup boosted their price target on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a £175 price target on shares of AstraZeneca in a report on Wednesday, September 9th. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of £150.

Check Out Our Latest Stock Report on AZN

AstraZeneca Trading Down 2.0%

Shares of AstraZeneca stock opened at £120.32 on Tuesday. The company’s 50-day moving average price is £121.50 and its 200-day moving average price is £132.85. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. AstraZeneca has a 12-month low of £114.04 and a 12-month high of £157.32. The company has a market cap of £186.60 billion, a price-to-earnings ratio of 18.01, a PEG ratio of 0.86 and a beta of 0.20.

Insider Buying and Selling at AstraZeneca

In other news, insider Michel Demare acquired 2,500 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were bought at an average cost of £121.21 per share, with a total value of £303,025. Corporate insiders own 0.15% of the company’s stock.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Featured Articles